XBiotech (XBIT) Share-based Compensation (2014 - 2026)

XBiotech has reported Share-based Compensation for 13 years, with the latest figure at $5.4 million in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 0.53% year-over-year to $5.4 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 0.53% increase from a year earlier, with the FY2025 full-year figure at $5.5 million, up 26.37% from the prior year.
• Share-based Compensation was $5.4 million for Q2 2026 at XBiotech, up from $162000.0 in the prior quarter.
• The five-year high for Share-based Compensation was $211.0 million in Q1 2025, with the low at $162000.0 in Q4 2025.
• Average Share-based Compensation over 5 years is $24.5 million, with a median of $4.7 million recorded in 2022.
• The largest YoY upside for Share-based Compensation was 4658.84% in 2025 against a maximum downside of 74.2% in 2025.
• Over 5 years, Share-based Compensation stood at $1.0 million in 2022, then plunged by 33.72% to $688000.0 in 2023, then fell by 8.72% to $628000.0 in 2024, then plunged by 74.2% to $162000.0 in 2025, then jumped by 3221.58% to $5.4 million in 2026.
• The last three Share-based Compensation figures came in at $5.4 million (Q2 2026), $162000.0 (Q4 2025), and $150.0 million (Q3 2025), per Business Quant data.